Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals ; volume:5 ; number:1 ; day:10 ; month:4 ; year:2012 ; pages:1-10 ; date:12.2012
BMC Research Notes / Biomed Central; 5, Heft 1 (10.4.2012), 1-10, 12.2012
- Creator
-
Martinez, Valrie
TA, Thi Dieu Ngan
Mokhtari, Zahra
Guiguet, Marguerite
Miailhes, Patrick
Valantin, Marc-Antoine
Charlotte, Frderic
Bertheau, Philippe
Molina, Jean-Michel
Katlama, Christine
Caumes, Eric
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-0500-5-180
- URN
-
urn:nbn:de:101:1-2019091914565338597327
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Martinez, Valrie
- TA, Thi Dieu Ngan
- Mokhtari, Zahra
- Guiguet, Marguerite
- Miailhes, Patrick
- Valantin, Marc-Antoine
- Charlotte, Frderic
- Bertheau, Philippe
- Molina, Jean-Michel
- Katlama, Christine
- Caumes, Eric
- SpringerLink (Online service)
Other Objects (12)
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Hepatitis C treatment initiation in HIV-HCV coinfected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders